Given that OC has been shown to inhibit MCL-1 [137]—a key resistance factor in venetoclax-treated MM and AML [216]—it is reasonable to anticipate potential synergism between OC and BCL-2 inhibitors such as venetoclax. The gene discussed is BCL2; the disease is acute myeloid leukemia.